In pursuit of an HIV cure, Gilead jumps into a T cell-driving vaccine program with a $785M deal that triggers PhI

John Carroll

Editor & Founder

After running through a lengthy stretch watching the market downshift expectations of its cancer pipeline, Gritstone Oncology has erupted with a quick set of advances …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In pursuit of an HIV cure, Gilead jumps into a T cell-driving vaccine program with a $785M deal that triggers PhI

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

ADCs from a decade-old Singapore biotech find new life with $187M

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

In pur­suit of an HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a $785M deal that trig­gers PhI

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

In pursuit of an HIV cure, Gilead jumps into a T cell-driving vaccine program with a $785M deal that triggers PhI